Premium
The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation
Author(s) -
Ronghe Milind D.,
Foot Annabel B. M.,
Cornish Jaqueline M.,
Steward Colin G.,
Carrington David,
Goulden Nicholas,
Marks David I.,
Oakhill Anthony,
Pamphilon Derwood H
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03746.x
Subject(s) - medicine , cytomegalovirus , betaherpesvirinae , transplantation , cytomegalovirus infection , disease , platelet , platelet transfusion , immunology , human cytomegalovirus , cohort , viral disease , herpesviridae , human immunodeficiency virus (hiv) , virus
Summary. The impact of transfusion of leucodepleted platelet concentrates (PCs) on cytomegalovirus (CMV) disease was assessed in 215 allogeneic (145 unrelated and 70 related donor) transplants over 3 years. In 43%, both donor and patient were CMV seronegative (CMV–/–). All received CMV‐seronegative red cells and random leucodepleted PCs. No CMV disease occurred in any CMV–/– (low risk) transplant. CMV infection occurred in 31 seropositive patients (26%); 13 died and five deaths were attributable to CMV disease. When compared with historical controls, who received CMV‐seronegative PCs, we found no difference in transfusion‐acquired CMV in the current cohort.